La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Sihuan Pharmaceutical Holdings Group Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Sihuan Pharmaceutical Holdings Group ha un patrimonio netto totale di CN¥5.1B e un debito totale di CN¥1.2B, che porta il suo rapporto debito/patrimonio netto a 22.9%. Le sue attività totali e le sue passività totali sono rispettivamente CN¥11.5B e CN¥6.4B.

Informazioni chiave

21.4%

Rapporto debito/patrimonio netto

CN¥1.09b

Debito

Indice di copertura degli interessi	n/a
Contanti	CN¥4.86b
Patrimonio netto	CN¥5.09b
Totale passività	CN¥6.44b
Totale attività	CN¥11.53b

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( CN¥6.2B ) di 460 superano le sue passività a breve termine ( CN¥4.1B ).

Passività a lungo termine: Le attività a breve termine di 460 ( CN¥6.2B ) superano le sue passività a lungo termine ( CN¥2.3B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: 460 ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di 460 è aumentato da 0.7% a 22.9% negli ultimi 5 anni.

Copertura del debito: Il debito di 460 non è ben coperto dal flusso di cassa operativo ( 17% ).

Copertura degli interessi: Dati insufficienti per determinare se i pagamenti degli interessi sul debito di 460 siano ben coperti dall'EBIT.

Sihuan Pharmaceutical Holdings Group Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Upcoming dividend of HK$0.021 per share

First half 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.005 loss in 1H 2023)

Sihuan Pharmaceutical Holdings Group Ltd. Announces Interim Ordinary Cash Dividend for the Six Months Ended June 30, 2024, Payable on 10 October 2024

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Sihuan Pharmaceutical Holdings Group Ltd.'s Honghe Pharmaceutical Co., Ltd. Obtains Drug Registration Approval from National Medical Products Administration

New major risk - Revenue and earnings growth

Sihuan Pharmaceutical Holdings Group Ltd. Announces Rivaroxaban Tablets (Strength: 2.5Mg) Obtained Drug Registration Approval from NMPA

Now 21% undervalued after recent price drop

Full year 2023 earnings released: CN¥0.006 loss per share (vs CN¥0.21 loss in FY 2022)

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: CN¥0.006 loss per share (vs CN¥0.21 loss in FY 2022)

Sihuan Pharmaceutical Holdings Group Ltd. Receives Registration Approval from National Medical Products Administration for Proline Janagliflozin Tablets

Now 20% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration of the People's Republic of China for the Treatment of Diabetes

National Medical Products Administration Approves IND Application of Insulin Degludec and Liraglutide Injection, Developed by Huisheng Biopharmaceutical

First half 2023 earnings released: CN¥0.005 loss per share (vs CN¥0.004 profit in 1H 2022)

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Sihuan Pharmaceutical Holdings Group Ltd. Announces Huisheng Biopharmaceutical's Drug Semaglutide Injection Obtained Approval for Clinical Trial

Sihuan Pharmaceutical Holdings Group Ltd. Announces Approval of Phase II Clinical Trial Application of Birociclib by the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration

Upcoming dividend of HK$0.037 per share at 9.7% yield

Full year 2022 earnings released: CN¥0.21 loss per share (vs CN¥0.044 profit in FY 2021)

Sihuan Pharmaceutical Holdings Group Ltd. Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Less than half of directors are independent

Sihuan Pharmaceutical Holdings Group Ltd. Announces Management Changes

Upcoming dividend of HK$0.037 per share

Sihuan Pharmaceutical Holdings Group Ltd. Declares Special Cash Dividend for the Six Months Ended 30 June 2022, Payable on or Around 13 October 2022

First half 2022 earnings released: EPS: CN¥0.004 (vs CN¥0.065 in 1H 2021)

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2022 Results on Aug 30, 2022

Sihuan Pharmaceutical Holdings Group Ltd. Provides Earnings Guidance for the Six Months Ended 30 June 2022

Sihuan Pharmaceutical Holdings Group Ltd. Announces Acceptance of Application for Marketing of Xuanzhu Biopharm\U0027s Drug Fulvestrant Injection by Nmpa of China

Upcoming dividend of HK$0.13 per share

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Sihuan Pharmaceutical Obtains Class III Medical Device Registration Certificate from NMPA for Exclusively Distributed Hyaluronic Acid Persnica

Now 20% undervalued

Full year 2021 earnings released: EPS: CN¥0.044 (vs CN¥0.054 in FY 2020)

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, May 24, 2022

Sihuan Pharmaceutical Holdings Group Ltd. Announces Ordinary Final Cash Dividend for the Year Ended December 31, 2021, Payable on June 14, 2022

Investor sentiment deteriorated over the past week

Now 25% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces First Class I Macromolecule Innovative Drug Her2 Bispecific Antibody Xzp-Km257 Was Approves for Clinical Trails

Investor sentiment improved over the past week

National Medical Products Administration Accepts Biologics License Application of Insulin Aspart Injection, Insulin Aspart 30 Injection and Insulin Aspart 50 Injection of Jilin Huisheng Biopharmaceutical Co., Ltd

Now 22% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces Medical Device Registration Certificate Obtained for Medical Skin Care Gel and Repair Gel

Sihuan Pharmaceutical Holdings Group Ltd. Announces Fondaparinux Sodium Injection Obtained Manufacture Approval

Investor sentiment deteriorated over the past week

First half 2021 earnings released: EPS CN¥0.065 (vs CN¥0.018 in 1H 2020)

Non-Executive Director Jin-ha Kim has left the company

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.016 per share

Sihuan Pharmaceutical Holdings Group Ltd. Announces Obtains Drug Registration Approval in Relation to Caspofungin Acetate for Injection

Sihuan Pharmaceutical Holdings Group Ltd. Recommends Final Cash Dividend for the Year Ended December 31, 2020, Payable on or Around July 15, 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Sihuan Pharmaceutical Holdings Group Ltd. Recommends Two Special Cash Dividends

Full year 2020 earnings released: EPS CN¥0.054 (vs CN¥0.29 loss in FY 2019)

Sihuan Pharmaceutical Holdings Group Ltd. to Report Fiscal Year 2020 Results on Mar 23, 2021

New 90-day high: HK$2.68

Sihuan Pharmaceutical Holdings Group Ltd. Announces Selection of its Pantoprazole Sodium Injection (Panzuoer® 40mg per unit) and Ibuprofen Injection (Falanfen® 4ml: 0.4g, Tenaan® 8ml: 0.8g) in the Fourth Batch of National Drug Centralized Procurement

Sihuan Pharmaceutical Holdings Group Ltd. Announces Cinepazide Maleate Injection Obtain Approval from the National Medical Products Administration

New 90-day high: HK$1.32

Upcoming Dividend of HK$0.035 Per Share

Sihuan Pharmaceutical Holdings Group Ltd.(SEHK:460) dropped from FTSE All-World Index (USD)

First half earnings released

Deputy General Manager recently bought HK$19m worth of stock

Earnings released

New 90-day high - HK$1.03

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2020 Results on Aug 25, 2020

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane